Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19640883 | 0.83 | ACHE (0.58) | AKR1C3HSD11B1MMP2ACHECA1 | |
| SCHEMBL19640887 | 0.83 | PSEN1 (0.57) | AKR1C3HSD11B1PSEN1PSEN2APH1B | |
| SCHEMBL19640858 | 0.83 | AKR1C3 (0.49) | ESR1AKR1C3HSD11B1PSEN1PSEN2 | |
| SCHEMBL19640791 | 0.82 | ACHE (0.54) | AKR1C3MMP2LMNAACHE | |
| SCHEMBL19640805 | 0.79 | ALDH1A1 (0.55) | AKR1C3HSD11B1MMP2LMNA | |
| SCHEMBL19640886 | 0.79 | AKR1C3 (0.52) | AKR1C3HSD11B1PSEN1PSEN2APH1B | |
| SCHEMBL2217801 | 0.77 | PSEN1 (0.62) | AKR1C3PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19640892 | 0.76 | AKR1C3 (0.52) | AKR1C3PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19640817 | 0.72 | AKR1C3 (0.49) | AKR1C3PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL19640794 | 0.72 | AKR1C3 (0.49) | AKR1C3PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464288-B1 | [8-(PHENYLSULFONYL)-3,8-DIAZABICYCLO[3.2.1]OCT-3-YL](1H-1,2,3-TRIAZOL-4-YL)METHANONES | Bayer Pharma AG (DE) | 2020-12-23 | — | — | EP | disclosed |
| EP-3464288-B1 | [8-(PHENYLSULFONYL)-3,8-DIAZABICYCLO[3.2.1]OCT-3-YL](1H-1,2,3-TRIAZOL-4-YL)METHANONES | Bayer Pharma AG (DE) | 2020-12-23 | — | — | EP | disclosed |
| US-10167293-B2 | [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-01 | — | — | US | disclosed |
| US-10167293-B2 | [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-01 | — | — | US | disclosed |
| US-20170342082-A1 | [8-(PHENYLSULFONYL)-3,8-DIAZABICYCLO[3.2.1]OCT-3-YL](1H-1,2,3-TRIAZOL-4-YL)METHANONES | Bayer Pharma AG (DE) | 2017-11-30 | — | — | US | disclosed |
| US-20170342082-A1 | [8-(PHENYLSULFONYL)-3,8-DIAZABICYCLO[3.2.1]OCT-3-YL](1H-1,2,3-TRIAZOL-4-YL)METHANONES | Bayer Pharma AG (DE) | 2017-11-30 | — | — | US | disclosed |
| US-20170342082-A1 | [8-(PHENYLSULFONYL)-3,8-DIAZABICYCLO[3.2.1]OCT-3-YL](1H-1,2,3-TRIAZOL-4-YL)METHANONES | Bayer Pharma AG (DE) | 2017-11-30 | — | — | US | disclosed |
| WO-2017202817-A1 | [8-(PHENYLSULFONYL)-3,8-DIAZABICYCLO[3.2.1]OCT-3-YL] (1H-1,2,3-TRIAZOL-4-YL)METHANONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342082-A1 | [8-(PHENYLSULFONYL)-3,8-DIAZABICYCLO[3.2.1]OCT-3-YL](1H-1,2,3-TRIAZOL-4-YL)METHANONES | PKD1, PKD2, PDK3 | ESR1 740/4885AKR1C3 45/4885HSD11B1 235/4885 |
| US-10167293-B2 | [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanones | PKD1, PKD2, PDK3 | ESR1 740/4885AKR1C3 45/4885HSD11B1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.